Acute Anaphylaxis Clinical Care Standard: 6c-Proportion of patients treated for anaphylaxis who require adrenaline injectors who are supplied or prescribed an adrenaline injector prior to separation from hospital.

Exported from METEOR

(AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website’s material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

# Acute Anaphylaxis Clinical Care Standard: 6c-Proportion of patients treated for anaphylaxis who require adrenaline injectors who are supplied or prescribed an adrenaline injector prior to separation from hospital.

|  |  |
| --- | --- |
| Identifying and definitional attributes | |
| Metadata item type: | Indicator |
| Indicator type: | Indicator |
| Short name: | 6c-Proportion of patients treated for anaphylaxis who require adrenaline injectors who are supplied or prescribed an adrenaline injector prior to separation from hospital. |
| METEOR identifier: | 745157 |
| Registration status: | [Australian Commission on Safety and Quality in Health Care](https://meteor.aihw.gov.au/RegistrationAuthority/18), Standard 24/11/2021 |
| Description: | Proportion of patients treated for anaphylaxis who require adrenaline injectors who are supplied or prescribed an adrenaline injector prior to separation from hospital. |
| Indicator set: | [Clinical care standard indicators: Acute Anaphylaxis](https://meteor.aihw.gov.au/content/745144)  [Australian Commission on Safety and Quality in Health Care](https://meteor.aihw.gov.au/RegistrationAuthority/18), Standard 24/11/2021 |

|  |  |
| --- | --- |
| Collection and usage attributes | |
| Population group age from: | All ages |
| Computation description: | For the numerator and denominator separations involving patients with anaphylaxis in hospital settings can be identified using the ICD codes specified in Table A.  **Table A: ICD-10-AM 11th edition codes for anaphylaxis**   |  |  | | --- | --- | | **Code** | **Description** | | T78.0 | Anaphylaxis and anaphylactic shock due to adverse food reaction | | T78.2 | Anaphylaxis and anaphylactic shock, unspecified | | T80.5 | Anaphylaxis and anaphylactic shock due to serum | | T88.6 | Anaphylaxis and anaphylactic shock due to adverse effect of correct drug or medicament properly administered |     Presented as a percentage. |
| Computation: | (Numerator ÷ Denominator) x 100​ |
| Numerator: | The number of patients treated for anaphylaxis who require adrenaline injectors who are supplied or prescribed an adrenaline injector prior to separation from hospital. |
| Denominator: | The number of patients treated for anaphylaxis who require an adrenaline injector. |
| Comments: | A patient should be given a personal adrenaline injector or a prescription for this medicine where there is a risk of re-exposure to the allergen.  Use of adrenaline injector is typically recommended for patients with:   * History of anaphylaxis * Food allergy (excluding oral allergy syndrome) and co-existing unstable or moderate to severe, persistent asthma * Underlying mast cell disorders.   For a comprehensive list of considerations to identify patients for whom use of adrenalin injectors are appropriate, please refer to the [ASCIA Guidelines - Adrenaline (Epinephrine) Autoinjector Prescription.](https://www.allergy.org.au/images/stories/anaphylaxis/2016/ASCIA_Guidelines_AAI_Prescription_2019.pdf) |
| Representational attributes | |
| Representation class: | Percentage |
| Data type: | Real |
| Unit of measure: | Person |
| Format: | N[NN] |
| Accountability attributes | |
| Other issues caveats: | Applicable settings: public and private hospitals. |
| Source and reference attributes | |
| Submitting organisation: | Australian Commission on Safety and Quality in Health Care |
| Reference documents: | Australian Commission on Safety and Quality in Health Care 2021. Acute Anaphylaxis clinical care standard. Australian Commission on Safety and Quality in Health Care, Sydney. |